Cargando…
Aspirin‐targeted PD‐L1 in lung cancer growth inhibition
BACKGROUND: Aspirin is a classic anti‐inflammatory drug and its anticancer effect has been previously explored in many types of cancer including colorectal cancer therapy. Programmed cell death‐ligand 1 (PD‐L1) is widely expressed in tumor cells and displays an inhibitory role in antitumor immunity....
Autores principales: | Zhang, Yixiang, Lv, Changsheng, Dong, Yan, Yang, Qingkai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262895/ https://www.ncbi.nlm.nih.gov/pubmed/32297484 http://dx.doi.org/10.1111/1759-7714.13433 |
Ejemplares similares
-
Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development
por: Xiao, Xiyun, et al.
Publicado: (2022) -
Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao, María, et al.
Publicado: (2015) -
PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023) -
Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy
por: Yan, Chen, et al.
Publicado: (2022) -
The combination of decitabine and aspirin inhibits tumor growth and
metastasis in non-small cell lung cancer
por: Xu, Maoyi, et al.
Publicado: (2022)